Along with unexpected benefits, medical specialists in South Florida also see patients grappling with the drawbacks of GLP-1 ...

GLP-1 receptor agonists are reshaping care for type 2 diabetes, obesity, chronic kidney disease, and obstructive sleep apnea, ...

Insurers are putting a growing focus on specialty drugs covered under the medical benefit, and on re-evaluating the efficacy ...

Emerging research suggests that taking most blood pressure medications at night, rather than in the morning, could significantly reduce risks of stroke, heart attack, and heart failure. The approach, ...

PSG’s research found that payers are placing more attention on specialty drugs covered under the medical benefit, showing ...

As many of us know, keeping weight in check can be hard. National numbers certainly reflect this. Rates of overweight and ...

When the U.S. Department of Justice moved to reclassify medical marijuana to a Schedule III drug on April 23, 2026, it set ...

University of Miami researchers found that type 2 diabetes drug metformin can help cancer patients by activating a molecule ...

Specialty drugs are an increasing worry for health plans and employers as new and innovative therapies enter the U.S. market ...

Researchers suggest that a simple explanation of the benefits and harms of a medication could improve a patient’s drug of choice, according to a Dartmouth College release. Previous research suggests ...

Twelve million people lost coverage for Zepbound over the last year. The same number of people lost coverage for Wegovy, ...

A comprehensive review of meta-analyses and clinical studies confirms GLP-1 receptor agonists, first developed for type 2 diabetes, offer benefits across cardiovascular, metabolic, renal, respiratory, ...